Safety issues of antiarrhythmic therapy for atrial fibrillation

I.I. Reznik , Ya.G. Bozhko

For citation:

Abstract

The article discusses the safety of antiarrhythmic therapy for atrial fibrillation in the light of the development of cardiac and non-cardiac side effects, the presence of drug-drug interactions of antiarrhythmic drugs in the near (with anticoagulants) and far circle. The features of the choice of antiarrhythmic therapy for the prevention of relapses of atrial fibrillation, restoration of sinus rhythm, as well as heart rate control are presented, and aspects of the tactics of managing these patients are highlighted.
Keywords: atrial fibrillation, antiarrhythmic therapy, side effects, drug-drug interactions.

References

1. Бойцов С.А., Шальнова С.А., Деев А.Д. Смертность от сердечно-сосудистых заболеваний в Российской Федерации и возможные механизмы ее изменения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(8):98-103. DOI: 10.17116/jnevro201811808198

Boytsov S.A., Shalnova S.A., Deev A.D. Cardiovascular mortality in the Russian Federation and possible mechanisms of itschanges. Zhurnal Nevrologii I Psikhiatrii imeni S.S. Korsakova. 2018;118(8):98 103. DOI: 10.17116/jnevro201811808198 (in Russian).

2. Go AS, Mozaffarian D, Roger VL et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129(3):28–292. DOI: 10.1161/01.cir.0000441139. 02102.80

3. Божко Я.Г., Архипов М.В., Молодых С.В. Особенности ведения пациентов с дисфункцией синусового узла неишемического генеза: в фокусе синдром тахибрадикардии. Уральский медицинский журнал. 2019;7(175):17-27.

Bozhko Ya.G., Arkhipov M.V., Molodykh S.V. Features of the management of patients with sinus node dysfunction of non-ischemic origin: tachy-bradycardia syndrome in focus. Ural Medical Journal. 2019;7(175):17-27. DOI: 10.25694/URMJ.2019.07.08 (in Russian).

4. Sheikh A, Patel NJ, Nalluri N et al. Trends in hospitalization for atrial fibrillation: epidemiology, cost, and implications for the future. Prog Cardiovasc Dis. 2015;58(2):105-16. DOI: 10.1016/j.pcad.2015.07.002

5. Krchhof P, Camm AJ, Goette A et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-16. DOI: 10.1056/NEJMoa2019422

6. Гайсёнок О.В. Особенности применения амиодарона в клинической практике: к вопросу о побочных эффектах препарата. Рациональная фармакотерапия в кардиологии. 2010;6(6):823-7. DOI:10.20996/1819-6446-2010-6-6-823-827

Gaisenok O.V. The use of amiodarone in clinical practice: the problem of side effects. Rational Pharmacother Card. 2010;6(6):823-7. DOI:10.20996/1819-6446-2010-6-6-823-827 (in Russian).

7. Кардиальные и эндокринные аспекты применения амиодарона в современной практике лечения нарушений ритма сердца. Методическое пособие. Под ред. Е.И. Чазова, И.И. Дедова. М.: Прототип, 2005.

Cardiac and endocrine aspects of the use of amiodarone in the modern practice of treating cardiac arrhythmias. Manual. Eds. E.I. Chazov,

I.I. Dedov. Moscow: Prototip, 2005 (in Russian).

8. You HS, Yoon JH, Cho SB et al. Amiodarone-Induced Multi-Systemic Toxicity Involving the Liver, Lungs, Thyroid, and Eyes: A Case Report. Front Cardiovasc Med. 2022;28:9:839441. DOI: 10.3389/fcvm.2022. 839441

9. Mikosch P. Thyroid and treatment with amiodarone diagnosis, therapy and clinical management. Wien Med Wochenschr. 2008; 158(1-2):29-35. DOI: 10.1007/s10354-007-0475-x

10. Lei M, Wu L, Terrar DA et al. Modernized Classification of Cardiac Antiarrhythmic Drugs. Circulation. 2018;138(17):1879-96. DOI: 10.1161/CIRCULATIONAHA.118.035455

11. McNamara RL, Tamariz LJ, Segal JB et al. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med. 2003; 139(12):1018-33. DOI: 10.7326/0003-4819-139-12-200312160-00012

12. Kapustnick Yu, Lutsenko R, Sуdorenko А. Combined pharmacological therapy including several antiarrhythmic agents for treatment of different disorders of cardiac rhythm. Georgian Med News. 2021;(315):85-93.

13. Hindricks G, Potpara T, Dagres Net et al. Рекомендации ESC 2020 по диагностике и лечению пациентов с фибрилляцией предсердий, разработанные совместно с Европейской ассоциацией кардиоторакальной хирургии (EACTS). Российский кардиологический журнал. 2021;26(9):4701. DOI: 10.15829/1560-4071-2021-4701

Hindricks G, Potpara T, Dagres Net et al. ESC 2020 guidelines for the diagnosis and treatment of patients with atrial fibrillation, developed jointly with the European Association of Cardiothoracic Surgery (EACTS). Russian Journal of Cardiology. 2021;26(9):4701. DOI: 10.15829/1560-4071-2021-4701 (in Russian).

14. Тарасов А.В., Косых С.А., Бушуева Е.В. и др. Сравнение эффективности инъекционных форм антиаритмических препаратов пропафенона и амиодарона при проведении фармакологической кардиоверсии пароксизмальной фибрилляции предсердий. Consilium Medicum. 2019;21(1):81-6.

Tarasov A.V., Kosykh S.A., Bushueva E.V. et al. Comparison of the effectiveness of injectable forms of antiarrhythmic drugs propafenone and amiodarone during pharmacological cardioversion of paroxysmal atrial fibrillation. Consilium Medicum. 2019;21(1):81-6 (in Russian).

15. Capucci А. Pill in the Pocket: A Safe and Useful Antiarrhythmic Strategy. JACC Clin Electrophysiol. 2022;8(12):1521-2. DOI: 10.1016/j.jacep. 2022.11.001

16. Freemantle N, Lafuente-Lafuente C, Mitchell S et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace. 2011;13(3):329-45. DOI: 10.1093/europace/euq450

17. Somberg J, Molnar J. Sotalol versus Amiodarone in Treatment of Atrial Fibrillation. J Atr Fibrillation. 2016;8(5):1359. DOI: 10.4022/jafib.1359

18. Anderson JL, Prystowsky EN. Sotalol: An important new antiarrhythmic. Am Heart J. 1999;137(3):388-409. DOI: 10.1016/s0002-8703(99)70484-9

19. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmcol Ther. 2013;138:103-41. DOI:10.1016/ j.pharmthera.2012.12.007

20. Herink MC, Zhuo YF, Williams СD et al. Clinical management of pharmacokinetic drug interactions with direct oral anticoagulants (DOACs). Drugs. 2019;79(15):625-34. DOI: 10.1007/s40265-019-01183-0

21. Voukalis С, Lip GY, Shantsila E. Drug-drug interactions of nonvitamin K oral anticoagulants. Expert Opin Drug Metab Toxicol. 2016;12(12): 1445-61. DOI: 10.1080/17425 255.2016.1225037

22. Mendell J, Zahir H, Ridout G et al. Drug-drug interaction studies of cardiovascular drugs (amiodarone, digoxin, quinidine, atorvastatin and verapamil) involving P-glycoprotein (P-gp), an efflux transporter, on the pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor (abstr). J Am Coll Cardiol. 2011;57:E1510. DOI: 10.1016/S0735-1097(11)61510-6

23. Konieczny K, Dorian P. Clinically Important Drug–Drug Interactions Between Antiarrhythmic Drugs and Anticoagulants. J Innov Cardiac Rhythm Manage. 2019;10(3):3552-9. DOI: 10.19102/icrm.2019. 100304

24. Mar PL, Horbal P, Chung et al MK. Drug Interactions Affecting Antiarrhythmic Drug Use. Circ Arrhythm Electrophysiol. 2022;15(5): e007955. DOI:10.1161/CIRCEP.121.007955

25. Dan GA, Martinez-Rubio A, Agewal S et al. Antiarrhythmic drugs–clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), AsiaPacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018;20(5):731-2an. DOI: 10.1093/europace/eux373

26. Sr DH, Nandkeolyar S, Lan H et al. Amiodarone: A Comprehensive Guide for Clinicians. Am J Cardiovasc Drugs. 2020;20(6):549-58. DOI: 10.1007/s40256-020-00401-5

For citation:Reznik I.I., Bozhko Ya.G. Safety issues of antiarrhythmic therapy for atrial fibrillation. Clinical review for general practice. 2024; 5 (1): 38–43 (In Russ.). DOI: 10.47407/kr2023.5.1.00358

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice